Merck Still Plans To Win Big Cost Savings This Year From Schering-Plough Deal
This article was originally published in The Pink Sheet Daily
Speaking at the Goldman Sachs Unplugged Conference, Merck CEO Clark says he brought in oilmen to help with modeling.
You may also be interested in...
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.